Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

Diabetic Macular Edema (DME) – Enhancement in Medical sector 2019 to 2025  Nevada Green Times

Methodology. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by ...

Effects of intravitreal bevacizumab in diabetic macular edema | Diabetes Research and Clinical Practice  MD Linx

Ophthalmology Article: Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic ...

Clearside Biomedical's Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society  GlobeNewswire

Presentations highlighted data analyses across multiple disease states -. - New, nonclinical data indicates potential for suprachoroidal administration of ...

Non-Infectious Macular Edema Treatment Market to reach a valuation of over US$ 17,200 Mn by the end of 2026 | Kentucky Breaking News Updates  Kentucky Journal 24

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular ...

Top News in Ophthalmology February 04 2019 (1 of 1)  MD Linx

Strong glycemic control may optimize vision outcomes in patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor ...

Regimen to macular edema | JAMA Ophthalmology  MD Linx

Internal Medicine Article: Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular ...

Aflibercept Reports Reduced Vision Loss in NPDR Patients Over 1 Year  MD Magazine

New PANORAMA phase 3 trial results add to the anti-VEGF's profile for treatment of diabetic retinopathy.

Anti-VEGF Efficacy in DME: Early Response Is Not Destiny  Medscape

New data from Protocol T shows that eyes with poor 12-week response often had good vision at 2 years without switching therapies.

This Valentine’s Day “Love your Eyes”  WKRC TV Cincinnati

CINCINNATI (WKRC) - Valentine's Day is a perfect opportunity to prompt your loved ones with diabetes to schedule their annual eye exam. If you or a loved one ...

Clearside Biomedical's Suprachoroidal Injection Platform to be Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society  BioSpace

Published: Feb 14, 2019. - Presentations will highlight data analyses across multiple disease states -. - New, nonclinical data indicates potential for ...

Macular Edema Market Projected to Witness Vigorous Expansion by 2025  Cryptocurrency News

Macula is the oval yellowish area surrounding the focal point of the retina in the eye. Macular edema is the state when liquid and protein begin collecting under ...

Diabetic Macular Edema Treatment Market Business Growth Strategies and Future Development Regeneron Pharmaceuticals Inc., Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd., Oculis, Bayer AG,  Journal Dairy

Diabetic Macular Edema Treatment market is having several developments, product launches, joint ventures, merges and accusations by its prominent market ...

Global 2019 Diabetic Macular Edema Market – Pipeline Insight  TOP Tribune

The Report on the “Diabetic Macular Edema Market” 2019 delivers extensive analysis of market trends and shares. The market shares of segments (players, ...

New Retinal Scanner Helps Diagnose Diabetic Retinopathy  The Parsons Advocate

ELKINS, W.Va. – A new technology at Davis Medical Center (DMC) is designed to help those with diabetes detect diabetic retinopathy in its early stages and ...

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium  PRNewswire

TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ -- Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious.

Global Diabetic Macular Edema (DME) Market 2019 by Type, Share, Growth, Trends and Forecast To 2025  reportsherald.com

Mart research Diabetic Macular Edema (DME) – Epidemiology Forecast, 2028 report provides a comprehensive analysis of the Diabetic Macular Edema (DME) ...

DIABETIC MACULAR EDEMA (DME) MARKET LANDSCAPE ASSESSMENT 2019 WITH TOTAL MARKET SHARE, DISTRIBUTION AND SWOT ANALYSIS AND FORECAST 2028  Journal Worldwide

Global Diabetic Macular Edema (DME) Market studies the present scenario of market (with the base year being 2019), Key Cross Competition, and the growth ...

Diabetic Macular Edema Treatment Market Comprehensive Analysis F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Alimera Sciences, ALLERGAN,  Bitcoin Journal

This report on Diabetic Macular Edema Treatment market focuses in the Diabetic Macular Edema Treatment market by explaining what the market definition, ...

Global 2019 Diabetic Macular Edema (DME) Market Insights, Epidemiology Forecast to 2028  Honest Version

The Report on the “Diabetic Macular Edema (DME) Market” 2018 delivers extensive analysis of market trends and shares. The market shares of segments ...

Regeneron (REGN) Announces 1-Yr. Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Regeneron Pharmaceuticals, Inc. (NASDAQ: ...

Global Diabetic Macular Edema Treatment Market Size, Trends, Status and Forecast 2019-2025  openPR

Looking at the current trends across the Diabetic Macular Edema Treatment market, a new study has been included to the wide database of Market Research ...

Macular Edema Therapeutics Market 2019 Pharmaceuticals & Healthcare Analysis – Allergan, Novartis, Roche, Regeneron Pharmaceuticals  Nevada Green Times

The report presents an in-depth assessment of the Macular Edema Therapeutics including enabling technologies, key trends, market drivers, challenges, ...

Global Diabetic Macular Edema (DME) – Market Insight, Epidemiology and Market Forecast – 2028 in Infectious Disease Therapeutic Area  NMSU Courier

Report Titled “Diabetic Macular Edema (DME) – Market Insight, Epidemiology and Market Forecast – 2028” provides product and API manufacturers' details ...

Global Diabetic Macular Edema Treatment Market 2018: Key Players, Size, Analysis, Sales and Production Forecast to 2022  Herald News Press

The Report strategically examines Diabetic Macular Edema Treatment Market with respect to growth trend, competitive developments, type, application and ...

Health Care Is About to Improve Dramatically; Here's How to Play it  TheStreet.com

Governments and physicians around the globe struggle to deliver high quality healthcare at a reasonable price. But *fresh* medical technology innovators are ...

Oxurion NV to Present at the 2019 BIO CEO & Investor Conference  P&T Community

Leuven, Belgium, 4 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision ...

Retinal Biologics Market Expected to Increase at a 11.1% CAGR Through 2028 - Future Market Insights  PRNewswire

VALLEY COTTAGE, New York, Feb. 5, 2019 /PRNewswire/ -- Retinal biologics market value surpassed US$ 14.6 billion in 2018 and projected to grow at 10.7% ...

Alimera Sciences Creates Eye Implant for Retinal Disease  Cheddar

Alimera Sciences is a company focuses on diseases impacted the retina (back of the eye). Diabetic Macular Edema, DME, is a disease that can cause blindness ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study.

Comparing of Nemaura Medical Inc. (NMRD) and IRIDEX Corporation (NASDAQ:IRIX)  The Hi New Ulm

Since Nemaura Medical Inc. (NASDAQ:NMRD) and IRIDEX Corporation (NASDAQ:IRIX) are part of the Medical Appliances & Equipment industry, they are ...

Characteristics of diabetic macular edema on optical coherence tomogra | OPTH  Dove Medical Press

Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment Shwu-Jiuan Sheu,1,2 Ying-Yen Lee,1 ...

Diabetic Macular Edema Market: Industry Statistics Report 2025; Alimera Sciences Inc., Regeneron Pharmaceuticals Inc., Pfizer Inc.  Eagle Chronicle

The Report Global Diabetic Macular Edema Market published by Crystal Market Research discusses the present as well as the predicted growing demand with ...

Statins May Reduce Risk of Retinopathy in Diabetes Patients  MD Magazine

Statins are already a common therapy among patients with type 2 diabetes. Its cholesterol-lowering benefits may help retain patient vision longer.

Treatment patterns in diabetic macular edema in Taiwan: a retrospectiv | OPTH  Dove Medical Press

Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review Shwu-Jiuan Sheu,1,2 Cheng-Kuo Cheng,3,4 Hsi-Kung Kuo,5 Ching-Yao ...

Taking too much sugar? Why your eyes may suffer  Daily Monitor

Diabetic eye disease is a group of eye conditions that affect people with diabetes due to unbalanced sugar levels in the body. It can affect many parts of the eye ...

Alimera Sciences wins Health Canada nod for diabetic macular edema implant  Mass Device

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien ...

Creative Planning Sells 950 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Fairfield Current

Creative Planning trimmed its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.2% during the fourth quarter, according to its most ...

Alimera's Iluvien OK'd in Lebanon  Seeking Alpha

Lebanon's Ministry of Health has approved Alimera Sciences' (ALIM +5.3%) ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic ...

Anti-VEGF Effective in Persistent Diabetic Macular Edema  Medscape

A recent analysis associated three different anti-VEGF agents with meaningful vision gains through 2 years of follow-up.

CIBC Private Wealth Group LLC Has $2.02 Million Position in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

CIBC Private Wealth Group LLC decreased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 20.6% in the fourth quarter, according to the ...

Contrasting of PLx Pharma Inc. (PLXP) and Coherus BioSciences Inc. (NASDAQ:CHRS)  The Hi New Ulm

Both PLx Pharma Inc. (NASDAQ:PLXP) and Coherus BioSciences Inc. (NASDAQ:CHRS) are each other's competitor in the Biotechnology industry. Thus the ...

Knight Therapeutics Inc. (GUD) EPS Estimated At $0.03; Last Week HomeServe plc (LON:HSV) Analysts  The Hi New Ulm

Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.03 EPS on March, 21.They anticipate $0.02 EPS change or 40.00% from last quarter's $0.05 ...

Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant  Cath Lab Digest

Verseon's precision oral anticoagulants (PROACs) could become the first anticoagulants suitable for long-term co-administration with antiplatelet agents for the ...

Pacific Biosciences of California Inc. (PACB)'s Financial Results Comparing With KalVista Pharmaceuticals Inc. (NASDAQ:KALV)  The Hi New Ulm

As Biotechnology businesses, Pacific Biosciences of California Inc. (NASDAQ:PACB) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV), are affected by ...

Risuteganib complements anti-VEGF treatment for diabetic macular edema  Healio

VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients ...

ThromboGenics completes first trial for new diabetic macular edema drug  Labiotech.eu

Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world's leading causes of vision loss.

Global Eye Care Surgical Devices Market Existent Outlook with Popular Manufactures are Carl Zeiss Meditec,Johnson & Johnson,Novartis,TOPCON,Valeant Pharmaceuticals,  Journal Worldwide

The Global Eye Care Surgical Devices Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified with the ...

CPAP for OSA Does Not Improve Diabetic Macular Edema or Visual Acuity  Pulmonology Advisor

Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) in patients with type 2 diabetes mellitus (T2DM) and diabetic macular ...

KalVista Pharmaceuticals Inc. (KALV) and Revance Therapeutics Inc. (NASDAQ:RVNC) Comparison side by side  The Hi New Ulm

As Biotechnology companies, KalVista Pharmaceuticals Inc. (NASDAQ:KALV) and Revance Therapeutics Inc. (NASDAQ:RVNC) are our subject to compare.

EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directors  Associated Press

WATERTOWN, Mass., Jan. 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company ...

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the.

KalVista To Pioneer Plasma Kallikrein Inhibitor Therapy For Diabetic Macular Edema  Seeking Alpha

Anti-VEGF therapy for diabetic macular edema (DME) is heralded as a miracle treatment. Granted, but there exists a significant subset of minimally- or ...

Knight Therapeutics Inc. (GUD) EPS Estimated At $0.03 | Thorold News  Thorold News

Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.03 EPS on March, 21.They anticipate $0.02 EPS change or 40.00 % from last quarter's $0.05 ...

After Reaching Milestone, Is Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE)'s Short Interest Revealing Something? | Thorold News  Thorold News

Investors sentiment increased to 2.56 in 2018 Q3. Its up 0.61, from 1.95 in 2018Q2. It improved, as 13 investors sold Ampio Pharmaceuticals, Inc. shares while.

Relationship Between Dry Retinal Volume and Visual Acuity in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the relationship between a novel spectral-domain optical ...

EyePoint Pharmaceuticals Announces US Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg  Associated Press

WATERTOWN, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company ...

Strategies of Key Players and Products Offered of Diabetic Macular Edema Treatment Market – Daily Updates  Daily Updates

Diabetic Macular Edema Treatment Market analysis is provided for global market including development trends by regions, competitive analysis of the Diabetic ...

Case Report on DME | Medpage Today  MedPage Today

An unexpected resolution of diabetic macular edema.

Ophthalmology Drugs Market Forecast 2025: Key players, Revenue Size & Share, Industry Analysis  Cryptocurrency News

Researchmoz added Most up-to-date research on “Global Ophthalmology Drugs Market Size, Status and Forecast 2019-2025” to its huge collection of research ...

One in four anti-VEGF therapy patients with DME lost to follow-up  Healio

A quarter of patients with diabetic macular edema who received an anti-VEGF injection to treat nonproliferative diabetic retinopathy did not return for a follow-up ...

The efficacy and safety of aflibercept and conbercept in diabetic macu | DDDT  Dove Medical Press

The efficacy and safety of aflibercept and conbercept in diabetic macular edema Siwei Cai, Qianhui Yang, Xiaorong Li, Yan Zhang Tianjin Medical University ...

Reviewing Alpine Immune Sciences Inc. (ALPN)'s and KalVista Pharmaceuticals Inc. (NASDAQ:KALV)'s results  The Yomi Blog

This is a contrast between Alpine Immune Sciences Inc. (NASDAQ:ALPN) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV) based on their analyst ...

What Will Happen to Alimera Sciences Inc (NASDAQ:ALIM) Next? The Stock Has Decline in Shorts | Thorold News  Thorold News

Investors sentiment increased to 2.25 in Q3 2018. Its up 1.32, from 0.93 in 2018Q2. It is positive, as 2 investors sold Alimera Sciences, Inc. shares while 6.

IRadimed Corporation (IRMD) and IRIDEX Corporation (NASDAQ:IRIX) Contrasting side by side  The Hi New Ulm

As Medical Appliances & Equipment companies, IRadimed Corporation (NASDAQ:IRMD) and IRIDEX Corporation (NASDAQ:IRIX) are our subject to contrast.

Research Analysts Offer Predictions for Regeneron Pharmaceuticals Inc’s Q2 2019 Earnings (REGN)  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Analysts at Jefferies Financial Group issued their Q2 2019 earnings per share estimates for Regeneron ...

Global Diabetic Macular Edema Treatment Market 2018-2022| Use of New Laser Delivery Systems to Boost Demand| Technavio  Business Wire

The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of over 1% during the forecast period, according to Technavio.

Reviewing Celyad SA (CYAD)'s and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)'s results  The Moveefy

Since Celyad SA (NASDAQ:CYAD) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) are part of the Biotechnology industry, they are influenced by compare.

Single Retinal Layer Changes After Subthreshold Micropulse Yellow Laser in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | A pilot prospective, interventional study has been conducted on 10 patients with diabetic macular edema ...

Regeneron Pharmaceuticals Inc. (REGN) and Cue Biopharma Inc. (NASDAQ:CUE) Contrasting side by side  Thе Mоnіtоr

Since Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Cue Biopharma Inc. (NASDAQ:CUE) are part of the Biotechnology industry, they are influenced ...

Tonix Pharmaceuticals Holding Corp. (TNXP)'s Financial Results Comparing With Clearside Biomedical Inc. (NASDAQ:CLSD)  The FinHeadLines

This is therefore a comparing of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Tonix.

Intrexon Corporation (XON)'s Financial Results Comparing With Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE)  The Moveefy

Intrexon Corporation (NASDAQ:XON) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) compete with each other in the Biotechnology sector. We will ...

World Diabetes Day 2018: What is diabetic macular edema? 5 superfoods to manage DME and improve eyesight  Times Now

World Diabetes Day, celebrated on November 14 every year, aims to raise awareness about diabetes prevention. And here are five superfoods that can help ...

Canada Pension Plan Investment Board Purchased 41449 Shares of Regeneron Pharmaceuticals Inc (REGN)  BharataPress

Canada Pension Plan Investment Board lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 39.2% in the fourth quarter, according ...

Reviewing Clearside Biomedical Inc. (CLSD)'s and Arbutus Biopharma Corporation (NASDAQ:ABUS)'s results  The FinHeadLines

Clearside Biomedical Inc. (NASDAQ:CLSD) and Arbutus Biopharma Corporation (NASDAQ:ABUS) compete with each other in the Biotechnology sector. We will ...

ICO Publishes New Guidelines for Diabetic Retinopathy  MD Magazine

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

Biomarkers May Predict Rx Response in Diabetic Macular Edema  Medscape

Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, ...

Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To describe the frequency and variation of intravitreal bevacizumab ...

TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.38; Hawk Ridge Management Lowered Insight Enterprises (NSIT) Holding By $2.03 Million  The FinHeadLines

Analysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.38 EPS on February, 27.They anticipate $0.01 EPS change or 2.70% from last ...

Reviewing OncoSec Medical Incorporated (ONCS)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  EN Digest

We will be contrasting the differences between OncoSec Medical Incorporated (NASDAQ:ONCS) and Clearside Biomedical Inc. (NASDAQ:CLSD) as far as ...

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial  BioSpace

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/ --. First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening ...

Intercontinental Wealth Advisors LLC Takes $33,000 Position in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

Intercontinental Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the 4th quarter, according to the ...

Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:The purpose of this study is to compare cancellation and no-show rates in ...

Fundus Camera Market Size, Emerging Evolution and Opportunities Till 2026 Appraised By Global Players Kowa Company Ltd.; Canon, Inc, Optomed Oy (Ltd.); Carl Zeiss Meditec, Inc.; Optovue Incorporated; NIDEK Co., Ltd.; Topcon Medical Systems, Inc.  openPR

Fundus camera is a specialized device with low power microscope, with an attached camera used to observe the fundus part. Its optical design is based on the ...

Patrik De Haes, MD: What's Coming Down the Retina Pipeline  MD Magazine

An anti-PIGF, a plasma kallikrein inhibitor, and a pan RGD integrin antagonist are some of the investigational treatments in the pipeline for diabetic retinopathy ...

FDA to Review Injection Treatment for Diabetic Retinopathy  Pharmacy Times

The FDA has accepted for review Regeneron Pharmaceuticals' supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat ...

Contrasting of Imprimis Pharmaceuticals Inc. (IMMY) and Equillium Inc. (NASDAQ:EQ)  The FinHeadLines

We are comparing Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) and Equillium Inc. (NASDAQ:EQ) on their risk, analyst recommendations, profitability, ...

Reviewing Vascular Biogenics Ltd. (VBLT)'s and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)'s results  The Moveefy

Both Vascular Biogenics Ltd. (NASDAQ:VBLT) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are Biotechnology companies, competing one another.

Regeneron Pharmaceuticals (REGN) Scheduled to Post Quarterly Earnings on Wednesday  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) will be issuing its quarterly earnings data before the market opens on Wednesday, February 6th. Analysts expect ...

Regeneron Pharmaceuticals (REGN) Stock Rating Reaffirmed by Cowen  Fairfield Current

Cowen reaffirmed their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday, January 7th. Cowen ...

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide | IMCRJ  Dove Medical Press

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with ...

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

Diabetic retinopathy position statement promotes prevention, early detection, control  Healio

A new position statement by the American Diabetes Association recommends intensive glycemic control and regular screening for prevention and early ...

Do Corticosteroids Improve Diabetic Macular Edema Outcomes?  Medscape

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 ...

Phase 3 trials to focus on Port Delivery System for AMD, faricimab for DME  Healio

Genentech and Roche announced the initiation of three large phase 3 clinical trials evaluating the Port Delivery System with ranibizumab to treat wet ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

Switching to Aflibercept from Ranibizumab Improved DME Outcomes  MD Magazine

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

Key Anti-VEGF Therapies Have Big Advantages and Drawbacks  MD Magazine

A new review of literature about 2 anti-VEGF therapies for diabetic macular edema suggest the drugs hold promise, but not without some caveats.

Chemotherapy-Induced Myelosuppression Treatment Market is Poised to Exhibit A Moderate 3.2% CAGR by 2028 - Future Market Insights  GlobeNewswire

Natural Product Intervention for Chemotherapy-induced Myelosuppression Treatment Points Gains Momentum: FMI Survey.

Diabetic Macular Edema Vastly Undertreated, Real-World Data Suggest  Medscape

Most patients with newly diagnosed diabetic macular edema are inadequately treated, according to findings from the American Academy of Ophthalmology's ...

Therapy applied directly inside the eye best for treating uveitic macular edema  Medical Xpress

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of ...

» Load more